SALUBRIS Trademark

Trademark Overview

On Tuesday, May 11, 2010, a trademark application was filed for SALUBRIS with the United States Patent and Trademark Office. The USPTO has given the SALUBRIS trademark a serial number of 79083827. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Tuesday, May 12, 2020. This trademark is owned by SHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD. The SALUBRIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; chemico-pharmaceutical preparations, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; chemical preparations for pharmaceutical purposes, namely, for treating diseases of cardiovas...
salubris

General Information

Serial Number79083827
Word MarkSALUBRIS
Filing DateTuesday, May 11, 2010
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateTuesday, May 12, 2020
Registration Number3972681
Registration DateTuesday, June 7, 2011
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, March 22, 2011

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesPharmaceutical preparations, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; chemico-pharmaceutical preparations, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; chemical preparations for pharmaceutical purposes, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; medicines for human purposes, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; troches, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; pharmaceutical products, namely, active pharmaceutical ingredients which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; prepared Chinese medicines, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; biochemical medicines, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; dietetic substances adapted for medical use, namely, beverages or food which are used for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; capsules for pharmaceutical purposes containing pharmaceutical preparations, specifically for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; drugs for medical purposes, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, October 12, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSHENZHEN 518000
CN
Party NameSHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCN
Party NameSHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSHENZHEN 518000
CN

Trademark Events

Event DateEvent Description
Friday, December 4, 2020NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Friday, December 4, 2020DEATH OF INTERNATIONAL REGISTRATION
Friday, September 27, 2019TOTAL INVALIDATION PROCESSED BY THE IB
Monday, July 1, 2019GENERIC MADRID TRANSACTION SENT TO IB
Monday, July 1, 2019GENERIC MADRID TRANSACTION CREATED
Wednesday, June 12, 2019TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, October 12, 2018CANCELLED SECTION 71
Wednesday, October 10, 2018CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, January 3, 2018POST REGISTRATION ACTION MAILED - SEC.71
Tuesday, December 19, 2017CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, December 6, 2017TEAS SECTION 71 RECEIVED
Wednesday, December 6, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 25, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, November 1, 2011FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, November 1, 2011FINAL DISPOSITION PROCESSED
Wednesday, September 7, 2011FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 7, 2011REGISTERED-PRINCIPAL REGISTER
Tuesday, March 22, 2011PUBLISHED FOR OPPOSITION
Thursday, March 3, 2011NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Thursday, March 3, 2011NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 2, 2011NOTICE OF PUBLICATION
Wednesday, February 16, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, February 11, 2011ASSIGNED TO LIE
Thursday, January 20, 2011CORRESPONDENCE MAILED
Wednesday, January 19, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 19, 2011EXAMINER'S AMENDMENT ENTERED
Wednesday, January 19, 2011EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 19, 2011TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 19, 2011CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 19, 2011TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 18, 2010REFUSAL PROCESSED BY IB
Wednesday, August 25, 2010NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, August 25, 2010REFUSAL PROCESSED BY MPU
Wednesday, August 25, 2010NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 24, 2010NON-FINAL ACTION WRITTEN
Tuesday, August 24, 2010ASSIGNED TO EXAMINER
Friday, July 23, 2010APPLICATION FILING RECEIPT MAILED
Monday, July 19, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, July 15, 2010SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

salubris system treating diseases namely pharmaceutical preparations immune endocrine digestive hypersensitivity